Physician profile
Lasandra Barton
NPI 1699777615
$3,894.07
in general payments reported to CMS, 2019-2025
27 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $20.16 · 2021: $197 · 2022: $27.16 · 2023: $1,117 · 2024: $747 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,988 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.94 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,097.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $729.82 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $329.84 | 2023-2025 | |
| Baxter Healthcare | $254.16 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.33 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $212.76 | 2019-2025 | Dupixent |
| Amgen INC. | $147.02 | 2023-2025 | Tezspire |
| Ethicon INC. | $133.16 | 2021 | |
| United Therapeutics Corporation | $121.54 | 2019-2025 | Tyvaso |
| Sunovion Pharmaceuticals INC. | $98.40 | 2019-2020 | |
| Inogen, INC. | $73.80 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Actelion Pharmaceuticals US, INC. | $57.69 | 2019 | |
| Pfizer INC. | $52.07 | 2023 | |
| Mylan Specialty L.P. | $51.85 | 2019-2023 | Yupelri |
| Viatris Specialty LLC | $39.29 | 2025 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $36.10 | 2023-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $34.13 | 2019-2024 | Keytruda |
| Gilead Sciences, INC. | $26.54 | 2019 | |
| Astellas Pharma US INC | $25.23 | 2024 | Cresemba |
| Genentech USA, INC. | $24.45 | 2019 | |
| Verona Pharma, INC. | $19.85 | 2025 | Ohtuvayre |
| Ucb, INC. | $17.21 | 2023 | Cimzia |
| Circassia INC. | $16.05 | 2019 | |
| Advanced Respiratory, INC | $15.90 | 2019 | |
| Shire North American Group INC | $15.62 | 2019 | |
| Abbvie INC. | $14.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lasandra Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.